Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Camurus AB ( (SE:CAMX) ) just unveiled an update.
Camurus’ Board of Directors has exercised its authorization to repurchase shares as part of its commitment to the Performance Share Plan 2025/2028. This strategic move involves the repurchase and conversion of 240,000 series C shares into common shares, effectively doubling the company’s holdings of common shares to 480,000, which is expected to enhance the company’s operational flexibility and shareholder value.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international, science-led biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines for patients with severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus is advancing a robust R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. The company operates in Europe, the US, and Australia, with its headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 99,997
Current Market Cap: SEK29.82B
See more insights into CAMX stock on TipRanks’ Stock Analysis page.